Status:
UNKNOWN
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
Lead Sponsor:
Jasper Therapeutics, Inc.
Conditions:
MYELODYSPLASTIC SYNDROME; MDS
ACUTE MYELOID LEUKEMIA; AML
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelody...
Detailed Description
This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine in subjects with Myelodys...
Eligibility Criteria
Inclusion
- Key
- AML/MDS as defined by specific criteria, including but not limited to the following subtypes:
- AML in CR
- MDS \< 5% BM blasts
- MDS 5 - 10% BM blasts
- AML not in CR or MDS \> 10% BM blasts
- Patients with human leukocyte antigen (HLA) matched related or unrelated donors
- Adequate end organ function as defined in study protocol
- Key
Exclusion
- Patients with any acute or uncontrolled infections
- Patients receiving any other investigational agents
- Patients with active non-hematologic malignancy
- Prior allogeneic hematologic cell transplantation
Key Trial Info
Start Date :
July 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 8 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04429191
Start Date
July 8 2020
End Date
December 8 2023
Last Update
June 11 2021
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
City of Hope Comprehensive Cancer Center
Duarte, California, United States, 91010
2
Stanford University
Stanford, California, United States, 94305
3
Rush University Medical Center
Chicago, Illinois, United States, 60612
4
Oregon Health & Science University
Portland, Oregon, United States, 97239